Nektar Therapeutics (NKTR) (Q3 2026) Earnings Call Highlights: Rezpeg Phase 3 Push and a $953 ...
Nektar Therapeutics (NKTR) launched Phase 3 trials for Rezpeg in atopic dermatitis and alopecia areata, touting a first-in-class T-reg mechanism and a debt-free balance sheet, though pivotal data Related Stocks: NKTR ,